Oruka Therapeutics, Inc. Business Combination, Consideration Transferred, Equity Interests Issued and Issuable
Oruka Therapeutics, Inc. (ORKA) reported Business Combination, Consideration Transferred, Equity Interests Issued and Issuable of $11.90 million for the 1-month period ending 2009-01-27, per its 10-Q filed 2014-05-13.
Discontinued › Notes › Business Combinations
us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable · last filed 2014-05-13
- 2009-01-27: Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 1 month $11.90M.
| Period end | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 1 month |
|---|---|
| 2009-01-27 | $11.90M 10-Q · filed 2014-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |